1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Radiation Dose Management Market
4. Market Overview
    4.1. Introduction
        4.1.1. Product Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Radiation Dose Management Market Analysis and Forecast, 2017-2031
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Key Product/Brand Analysis
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry
6. Global Radiation Dose Management Market Analysis and Forecast, by Product and Services
    6.1. Introduction and Definitions
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Product and Services, 2017–2031
        6.3.1. Software
            6.3.1.1. Integrated Solution
            6.3.1.2. Standalone Solution
        6.3.2. Services
    6.4. Market Attractiveness, by Product and Services
7. Global Radiation Dose Management Market Analysis and Forecast, by Modality
    7.1. Introduction and Definitions
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Modality, 2017–2031
        7.3.1. Computed Tomography
        7.3.2. Radiography and Mammography
        7.3.3. Fluoroscopy and Interventional Imaging
        7.3.4. Nuclear Medicine Scan
        7.3.5. Others
        7.3.6. 7.4 Market Attractiveness, by Modality
8. Global Radiation Dose Management Market Analysis and Forecast, by Application
    8.1. Introduction and Definitions
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Application, 2017–2031
        8.3.1. Oncology
        8.3.2. Cardiology
        8.3.3. Orthopedic
        8.3.4. Others
    8.4. Market Attractiveness, by Application
9. Global Radiation Dose Management Market Analysis and Forecast, by End-user
    9.1. Introduction and Definitions
    9.2. Key Findings/Developments
    9.3. Market Value Forecast, by End-user, 2017–2031
        9.3.1. Hospitals
        9.3.2. Ambulatory Care Settings
        9.3.3. Research Organizations
        9.3.4. Others
    9.4. Market Attractiveness, by End-user
10. Global Radiation Dose Management Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region, 2017–2031
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness, by Region
11. North America Radiation Dose Management Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Product and Services, 2017–2031
        11.2.1. Software
            11.2.1.1. Integrated Solution
            11.2.1.2. Standalone Solution
        11.2.2. Services
    11.3. Market Attractiveness, by Product and Services
    11.4. Market Value Forecast, by Modality, 2017–2031
        11.4.1. Computed Tomography
        11.4.2. Radiography and Mammography
        11.4.3. Fluoroscopy and Interventional Imaging
        11.4.4. Nuclear Medicine Scan
        11.4.5. Others
    11.5. Market Attractiveness, by Modality
    11.6. Market Value Forecast, by Application, 2017–2031
        11.6.1. Oncology
        11.6.2. Cardiology
        11.6.3. Orthopedic
        11.6.4. Others
    11.7. Market Attractiveness, by Application
    11.8. Market Value Forecast, by End-user, 2017–2031
        11.8.1. Hospitals
        11.8.2. Ambulatory Care Settings
        11.8.3. Research Organizations
        11.8.4. Others
    11.9. Market Attractiveness, by End-user
    11.10. Market Value Forecast, by Country/Sub-region, 2017–2031
        11.10.1. U.S.
        11.10.2. Canada
    11.11. Market Attractiveness Analysis
        11.11.1. By Product and Services
        11.11.2. By Modality
        11.11.3. By Application
        11.11.4. By End-user
        11.11.5. By Country
12. Europe Radiation Dose Management Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Product and Services, 2017–2031
        12.2.1. Software
            12.2.1.1. Integrated Solution
            12.2.1.2. Standalone Solution
        12.2.2. Services
    12.3. Market Attractiveness, by Product and Services
    12.4. Market Value Forecast, by Modality, 2017–2031
        12.4.1. Computed Tomography
        12.4.2. Radiography and Mammography
        12.4.3. Fluoroscopy and Interventional Imaging
        12.4.4. Nuclear Medicine Scan
        12.4.5. Others
    12.5. Market Attractiveness, by Modality
    12.6. Market Value Forecast, by Application, 2017–2031
        12.6.1. Oncology
        12.6.2. Cardiology
        12.6.3. Orthopedic
        12.6.4. Others
    12.7. Market Attractiveness, by Application
    12.8. Market Value Forecast, by End-user, 2017–2031
        12.8.1. Hospitals
        12.8.2. Ambulatory Care Settings
        12.8.3. Research Organizations
        12.8.4. Others
    12.9. Market Attractiveness, by End-user
    12.10. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.10.1. Germany
        12.10.2. U.K.
        12.10.3. France
        12.10.4. Italy
        12.10.5. Spain
        12.10.6. Rest of Europe
    12.11. Market Attractiveness Analysis
        12.11.1. By Product and Services
        12.11.2. By Modality
        12.11.3. By Application
        12.11.4. By End-user
        12.11.5. By Country/Sub-region
13. Asia Pacific Radiation Dose Management Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Product and Services, 2017–2031
        13.2.1. Software
            13.2.1.1. Integrated Solution
            13.2.1.2. Standalone Solution
        13.2.2. Services
    13.3. Market Attractiveness, by Product and Services
    13.4. Market Value Forecast, by Modality, 2017–2031
        13.4.1. Computed Tomography
        13.4.2. Radiography and Mammography
        13.4.3. Fluoroscopy and Interventional Imaging
        13.4.4. Nuclear Medicine Scan
        13.4.5. Others
    13.5. Market Attractiveness, by Modality
    13.6. Market Value Forecast, by Application, 2017–2031
        13.6.1. Oncology
        13.6.2. Cardiology
        13.6.3. Orthopedic
        13.6.4. Others
    13.7. Market Attractiveness, by Application
    13.8. Market Value Forecast, by End-user, 2017–2031
        13.8.1. Hospitals
        13.8.2. Ambulatory Care Settings
        13.8.3. Research Organizations
        13.8.4. Others
    13.9. Market Attractiveness, by End-user
    13.10. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.10.1. China
        13.10.2. Japan
        13.10.3. India
        13.10.4. Australia & New Zealand
        13.10.5. Rest of Asia Pacific
    13.11. Market Attractiveness Analysis
        13.11.1. By Product and Services
        13.11.2. By Modality
        13.11.3. By Application
        13.11.4. By End-user
        13.11.5. By Country/Sub-region
14. Latin America Radiation Dose Management Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Product and Services, 2017–2031
        14.2.1. Software
            14.2.1.1. Integrated Solution
            14.2.1.2. Standalone Solution
        14.2.2. Services
    14.3. Market Attractiveness, by Product and Services
    14.4. Market Value Forecast, by Modality, 2017–2031
        14.4.1. Computed Tomography
        14.4.2. Radiography and Mammography
        14.4.3. Fluoroscopy and Interventional Imaging
        14.4.4. Nuclear Medicine Scan
        14.4.5. Others
    14.5. Market Attractiveness, by Modality
    14.6. Market Value Forecast, by Application, 2017–2031
        14.6.1. Oncology
        14.6.2. Cardiology
        14.6.3. Orthopedic
        14.6.4. Others
    14.7. Market Attractiveness, by Application
    14.8. Market Value Forecast, by End-user, 2017–2031
        14.8.1. Hospitals
        14.8.2. Ambulatory Care Settings
        14.8.3. Research Organizations
        14.8.4. Others
    14.9. Market Attractiveness, by End-user
    14.10. Market Value Forecast, by Country/Sub-region, 2017–2031
        14.10.1. Brazil
        14.10.2. Mexico
        14.10.3. Rest of Latin America
    14.11. Market Attractiveness Analysis
        14.11.1. By Product and Services
        14.11.2. By Modality
        14.11.3. By Application
        14.11.4. By End-user
        14.11.5. By Country/Sub-region
15. Middle East & Africa Radiation Dose Management Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Product and Services, 2017–2031
        15.2.1. Software
            15.2.1.1. Integrated Solution
            15.2.1.2. Standalone Solution
        15.2.2. Services
    15.3. Market Attractiveness, by Product and Services
    15.4. Market Value Forecast, by Modality, 2017–2031
        15.4.1. Computed Tomography
        15.4.2. Radiography and Mammography
        15.4.3. Fluoroscopy and Interventional Imaging
        15.4.4. Nuclear Medicine Scan
        15.4.5. Others
    15.5. Market Attractiveness, by Modality
    15.6. Market Value Forecast, by Application, 2017–2031
        15.6.1. Oncology
        15.6.2. Cardiology
        15.6.3. Orthopedic
        15.6.4. Others
    15.7. Market Attractiveness, by Application
    15.8. Market Value Forecast, by End-user, 2017–2031
        15.8.1. Hospitals
        15.8.2. Ambulatory Care Settings
        15.8.3. Research Organizations
        15.8.4. Others
    15.9. Market Attractiveness, by End-user
    15.10. Market Value Forecast, by Country/Sub-region, 2017–2031
        15.10.1. GCC Countries
        15.10.2. South Africa
        15.10.3. Rest of Middle East & Africa
    15.11. Market Attractiveness Analysis
        15.11.1. By Product and Services
        15.11.2. By Modality
        15.11.3. By Application
        15.11.4. By End-user
        15.11.5. By Country/Sub-region
16. Competition Landscape
    16.1. Market Player -Competition Matrix (By Tier and Size of Companies)
    16.2. Market Share Analysis, by Company (2022)
    16.3. Company Profiles
        16.3.1. Landauer
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Product Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. Agfa-Gevaert Group
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Product Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. Sectra AB
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Product Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. INFINITT Healthcare Co. Ltd.
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Product Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. Bayer AG
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Product Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. PACSHealth, LLC
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Product Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. Koninklijke Philips N.V.
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Product Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. GE Healthcare
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Product Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview
        16.3.9. Thermo Fisher Scientific, Inc.
            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.9.2. Product Portfolio
            16.3.9.3. Financial Overview
            16.3.9.4. SWOT Analysis
            16.3.9.5. Strategic Overview
        16.3.10. Medsquare SAS
            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.10.2. Product Portfolio
            16.3.10.3. Financial Overview
            16.3.10.4. SWOT Analysis
            16.3.10.5. Strategic Overview
        16.3.11. Siemens
            16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.11.2. Product Portfolio
            16.3.11.3. Financial Overview
            16.3.11.4. SWOT Analysis
            16.3.11.5. Strategic Overview
        16.3.12. Fujifilm Holdings Corporation
            16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.12.2. Product Portfolio
            16.3.12.3. Financial Overview
            16.3.12.4. SWOT Analysis
            16.3.12.5. Strategic Overview
        16.3.13. QAELUM NV
            16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.13.2. Product Portfolio
            16.3.13.3. Financial Overview
            16.3.13.4. SWOT Analysis
            16.3.13.5. Strategic Overview
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


 
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			